{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:19Z","timestamp":1753892119106,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) is relatively less studied.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> Clinical data of patients with HER2-positive eBC treated with PLD and cyclophosphamide (PLD-C) followed by taxanes plus trastuzumab \u00b1 pertuzumab (TH or TPH) who then completed standard anti-HER2 treatment for 12\u00a0months from June 2012 to August 2021 were retrospectively collected. The primary endpoints were clinical and subclinical cardiotoxicity.<\/jats:p><jats:p><jats:bold>Result:<\/jats:bold> In total, 70 eligible patients were enrolled. Among them, 55 patients (78.6%) received PLD-C \u2192 TH and 15 patients (21.4%) received PLD-C \u2192 TPH. The median follow-up time was 41.8 months. Until August 2021, only two patients had recurrent or metastatic diseases, with 2-year and 5-year disease-free survivals of 98.6% and 96.8%, respectively. Clinical cardiotoxicity occurred in six patients (8.6%), and all of them had an absolute decline of \u226516% from baseline left ventricular ejection fraction (LVEF) but not below the lower limit of normal (LLN = 50%). Subclinical cardiotoxicity events occurred in 17 patients (24.3%), and all of them had absolute declines of \u226510% and &amp;lt;16% from baseline LVEF but not below the LLN. No patients were interrupted from treatment, and all patients completed anti-HER2 treatment for 12\u00a0months. The sharpest decrease in LVEF was observed at 18 months after the start of PLD treatment. The cumulative incidences of clinical and subclinical cardiotoxicity were 9.8% and 28.3%, respectively. In the univariate analysis, body mass index, age, left chest wall radiotherapy, and ongoing cardiovascular risk factors were not significantly associated with clinical or subclinical cardiotoxicity (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). No patients had congestive heart failure or death caused by PLD or anti-HER2 treatment.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The sequential use of PLD and trastuzumab showed a lower incidence of clinical cardiotoxicity, presented as asymptomatic decreased LVEF, compared with the results obtained in previous clinical studies using conventional anthracycline, taxanes and trastuzumab. The study regimen demonstrated good cardiac tolerance and is an alternative strategy for cardioprotection in patients with HER2-positive eBC.<\/jats:p>","DOI":"10.3389\/fphar.2022.883600","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T06:50:40Z","timestamp":1659595840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-bing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-ming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-ying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan-hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"Advani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 Years' Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Adjuvant (HERA) Trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An Open-Label Study to Evaluate Dose and Cycle Dependence of the Pharmacokinetics of Pegylated Liposomal Doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): a Randomised Multicentre, Open-Label, Phase 2 Trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"645026","DOI":"10.3389\/fonc.2021.645026","article-title":"Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study","volume":"11","author":"Gil-Gil","year":"2021","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 Years versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1002989","DOI":"10.1371\/journal.pmed.1002989","article-title":"Association of Body Mass Index and Cardiotoxicity Related to Anthracyclines and Trastuzumab in Early Breast Cancer: French CANTO Cohort Study","volume":"16","author":"Kabor\u00e9","year":"2019","journal-title":"PLoS Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41598-020-80415-w","article-title":"Higher Efficacy and Reduced Adverse Reactions in Neoadjuvant Chemotherapy for Breast Cancer by Using Pegylated Liposomal Doxorubicin Compared with Pirarubicin","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.2016-0412","article-title":"SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function","volume":"22","author":"Lynce","year":"2017","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.26355\/eurrev_201804_14752","article-title":"Anthracycline and Trastuzumab-Induced Cardiotoxicity in Breast Cancer","volume":"22","author":"Nicolazzi","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX\/Doxil) versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular Disease Competes with Breast Cancer as the Leading Cause of Death for Older Females Diagnosed with Breast Cancer: a Retrospective Cohort Study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) with ACP Plus Trastuzumab as Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2-positive Breast Cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab Plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: a Randomized Phase II Cardiac Safety Study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.breast.2016.03.003","article-title":"Short Term Quality of Life with Epirubicin-Fluorouracil-Cyclophosphamid (FEC) and Sequential Epirubicin\/cyclophosphamid-Docetaxel (EC-DOC) Chemotherapy in Patients with Primary Breast Cancer - Results from the Prospective Multi-Center Randomized ADEBAR Trial","volume":"27","author":"Schwentner","year":"2016","journal-title":"Breast"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients with HER2-Positive Metastatic Breast Cancer in CLEOPATRA: a Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","article-title":"Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer","volume":"21","author":"Yu","year":"2016","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab Interruption and Treatment-Induced Cardiotoxicity in Early HER2-Positive Breast Cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.883600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T06:50:41Z","timestamp":1659595841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.883600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":24,"alternative-id":["10.3389\/fphar.2022.883600"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.883600","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"article-number":"883600"}}